查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1561455

2024-2032 年按技術、應用、最終用戶和地區分類的藥物基因組學市場報告

Pharmacogenomics Market Report by Technology, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2023年全球藥物基因體學市場IMARC Group達79億美元。

藥物基因體學是研究人類基因對特定藥物反應的遺傳變異。它利用藥理學和基因組學的原理來開發根據個體基因組成客製化的有效且安全的藥物。它涉及多種技術的使用，例如聚合酶鏈反應（PCR）、微陣列、脫氧核糖核酸（DNA）測序、質譜和電泳。藥物基因組學中進行的基因測試有助於確定對某些疾病的易感性和新開發藥物的功效。藥物基因體學也廣泛應用於各種疾病的治療，如心血管、阿茲海默症、癌症、人類免疫缺陷病毒和後天免疫缺乏症候群（HIV/AIDS）和氣喘。

藥物基因組學市場趨勢：

全球製藥業的顯著成長是創造積極市場前景的關鍵因素之一。此外，對提高藥物安全性的精準藥物的需求不斷成長，也推動了市場的成長。隨著慢性生活方式疾病的日益流行，副作用最小且療效提高的標靶藥物治療被廣泛採用。與此一致，藥物基因組學也廣泛用於癌症治療，並預測化療和標靶免疫生物製劑可能的藥物反應、抗藥性、功效和毒性，這也促進了市場的成長。此外，各種技術進步，例如藥物基因組生物標記標記解決方案的開發，也是其他生長誘導因素。它們有助於最大限度地降低體內可避免的藥物不良反應 (ADR) 的風險並改善臨床結果。其他因素，包括廣泛的研發 (R&D) 活動以及醫療保健基礎設施的顯著改善，預計將推動市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球藥物基因組學市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球藥物基因體學市場有何影響？
  • 主要區域市場有哪些？
  • 基於技術的市場區隔是什麼？
  • 基於應用的市場區隔是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球藥物基因體學市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球藥物基因體學市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依技術

  • 聚合酶鍊式反應
    • 市場趨勢
    • 市場預測
  • 微陣列
    • 市場趨勢
    • 市場預測
  • DNA定序
    • 市場趨勢
    • 市場預測
  • 質譜分析
    • 市場趨勢
    • 市場預測
  • 電泳
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按應用

  • 腫瘤學
    • 市場趨勢
    • 市場預測
  • 傳染病
    • 市場趨勢
    • 市場預測
  • 心血管疾病
    • 市場趨勢
    • 市場預測
  • 神經系統疾病
    • 市場趨勢
    • 市場預測
  • 精神病學
    • 市場趨勢
    • 市場預測
  • 疼痛管理
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院和診所
    • 市場趨勢
    • 市場預測
  • 學術及研究機構
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • AstraZeneca plc
    • Bayer AG
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Illumina Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Myriad Genetics Inc.
    • Qiagen NV
    • Thermo Fisher Scientific Inc
Product Code: SR112024A4396

The global pharmacogenomics market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 16.1 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032.

Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.

Pharmacogenomics Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmacogenomics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technology, application and end user.

Breakup by Technology:

  • Polymerase Chain Reaction
  • Microarray
  • DNA Sequencing
  • Mass Spectrometry
  • Electrophoresis
  • Others

Breakup by Application:

  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Psychiatry
  • Pain Management
  • Others

Breakup by End User:

  • Hospitals and Clinics
  • Academic and Research Institutes

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

  • How has the global pharmacogenomics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pharmacogenomics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global pharmacogenomics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacogenomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Polymerase Chain Reaction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Microarray
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Sequencing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mass Spectrometry
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Electrophoresis
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Infectious Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cardiovascular Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Neurological Diseases
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Psychiatry
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Pain Management
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Academic and Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GlaxoSmithKline plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Illumina Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Johnson & Johnson
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Myriad Genetics Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Qiagen N.V.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Thermo Fisher Scientific Inc
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmacogenomics Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacogenomics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Pharmacogenomics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Pharmacogenomics Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Pharmacogenomics Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Pharmacogenomics Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Pharmacogenomics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Pharmacogenomics (Polymerase Chain Reaction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Pharmacogenomics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Pharmacogenomics (Microarray) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Pharmacogenomics (Microarray) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Pharmacogenomics (DNA Sequencing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Pharmacogenomics (DNA Sequencing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Pharmacogenomics (Mass Spectrometry) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Pharmacogenomics (Mass Spectrometry) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Pharmacogenomics (Electrophoresis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Pharmacogenomics (Electrophoresis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Pharmacogenomics (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Pharmacogenomics (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Pharmacogenomics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Pharmacogenomics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Pharmacogenomics (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Pharmacogenomics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Pharmacogenomics (Cardiovascular Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Pharmacogenomics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Pharmacogenomics (Neurological Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Pharmacogenomics (Neurological Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Pharmacogenomics (Psychiatry) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Pharmacogenomics (Psychiatry) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Pharmacogenomics (Pain Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Pharmacogenomics (Pain Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Pharmacogenomics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Pharmacogenomics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Pharmacogenomics (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Pharmacogenomics (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Pharmacogenomics (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Pharmacogenomics (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: North America: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: North America: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: United States: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: United States: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Canada: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Canada: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Asia-Pacific: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Asia-Pacific: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: China: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: China: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Japan: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Japan: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: India: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: India: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: South Korea: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: South Korea: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Australia: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Australia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Indonesia: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Indonesia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Europe: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Europe: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Germany: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Germany: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: France: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: France: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: United Kingdom: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: United Kingdom: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Italy: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Italy: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Spain: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Spain: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Russia: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Russia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Latin America: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Latin America: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Brazil: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Brazil: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Mexico: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Mexico: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Middle East and Africa: Pharmacogenomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Middle East and Africa: Pharmacogenomics Market: Breakup by Country (in %), 2023
  • Figure 86: Middle East and Africa: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Global: Pharmacogenomics Industry: SWOT Analysis
  • Figure 88: Global: Pharmacogenomics Industry: Value Chain Analysis
  • Figure 89: Global: Pharmacogenomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacogenomics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pharmacogenomics Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Pharmacogenomics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Pharmacogenomics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Pharmacogenomics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Pharmacogenomics Market: Competitive Structure
  • Table 7: Global: Pharmacogenomics Market: Key Players